Page 5 - Aurobindo Pharma

Strong injectables portfolio to support Aurobindo Pharma's growth

The stock has been underperforming recent months and trades at a discount to peers

Aurobindo Pharma steady as analysts watch numbers for near-term growth

The company's investments across segments will take at least two years to play out, say analysts

Aurobindo Pharma Q3 net profit zooms over four-fold to Rs 2,946.32 cr

Aurobindo Pharma reported an over four-fold jump in its consolidated net profit to Rs 2,946.32 crore for the quarter ended December 31, 2020 mainly on account of one time exceptional gains.

Aurobindo gains 5% on govt nod for promotion of manufacturing bulk drugs

Aurobindo Pharma (through Lyfius Pharma) has received government approval for setting up plants for production of Penicillin-G and 7-ACA, under the PLI scheme

Aurobindo Pharma, KAPL get nod for promotion of manufacturing bulk drugs

The government has given approval to drug firms includingAurobindo Pharma and Karnataka Antibiotics & Pharmaceuticals under the PLI scheme for promotion of domestic manufacturing of critical bulk drugs. The Production Linked Incentive (PLI) scheme aims at promotion of manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country. The setting up of plants under the scheme will lead to total committed investment of Rs 3,761 crore by the companies and employment generation for around 3,825 people,the Ministry of Chemicals and Fertilizers said in a statement. The applications of Aurobindo Pharma (through Lyfius Pharma) have been approved for setting up plants for the production ofPenicillin G, and 7-ACA, with committed production capacity of15,000 MT and2,000 MT, respectively. The committed investment for Penicillin G is Rs1,392 crore, and for 7-ACA isRs 813 crore, it added. The approval has also been given to Aurobindo Pharma (through Qule Pharma)

Pharma, healthcare growing, but they face challenges beyond Covid-19

These sectors will face another tough year after coronavirus pandemic, the first challenge being vaccination of India's 1.3 billion people. Devangshu Datta explains the opportunities and threats

India Coronavirus Dispatch: Nod to Covaxin raises many eyebrows

Other vaccines being developed in India, dangerous conspiracy theories, private hospitals keen on jumping in-news relevant to India's fight against Covid-19

Here's a Bull Spread Strategy on Aurobindo Pharma by HDFC Securities

The stock price has broken out from the downward slopping trendline

Aurobindo Pharma joins hands with Covaxx for coronavirus vaccine

According to a release issued by the drug maker, Covaxx is currently conducting a Phase 1 clinical trial for the vaccine candidate

Aurobindo Pharma gets USFDA approval for drug used to sedate patients

Drug major Aurobindo Pharma said it has received final approval from the US health regulator for generic of Precedex injection, used for sedation of patients

Aurobindo Pharma completes sale of US subsidiary's Natrol to New Mountain

Drug firm Aurobindo Pharma said it has completed the sale of Natrol LLC, a wholly-owned unit of its US-based subsidiary, to private equity firm New Mountain Capital

Aurobindo Pharma expects to commercialise Covid-19 vaccine facility by May

Aurobindo Pharma expects to commercialise its Covid-19 vaccine manufacturing facility in Hyderabad by April-May next year, according to a top company official

Weekly stock picks by Religare Broking: Buy Aurobindo Pharma, Marico

The chart pattern and positioning of oscillators are pointing towards a sharp up move in Aurobindo Pharma in the near future

Pfizer moves US court against Aurobindo Pharma, Dr Reddy's on cancer drug

Pfizer Inc alleged that the drug makers were planning separately to come out with generic versions of its blockbuster multi-billion dollar drug Ibrance (palbociclib) before expiration of its patent

Aurobindo, Zydus, Jubilant, others recall various products in US market

Indian drug firms like Marksans Pharma, Aurobindo Pharma, Zydus and Jubilant are recalling products in the US market, as per the latest enforcement report by the USFDA

Aurobindo Pharma rallies 6% as Q2 net profit rises 26% YoY to Rs 805.65 cr

The company's consolidated total revenue from operations stood at Rs 6,483.44 crore.

Aurobindo Pharma reports 26% increase in Q2 net profit at Rs 805 crore

The company said it received final approval for 10 ANDAs (abbreviated new drug applications) from USFDA

Bull run continues; Sensex up 316 pts to end at 43,594, Nifty nears 12,750

All that happened in the markets today.

Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

Top headlines: Aurobindo Pharma to sell Natrol; Navratri drives car sales

From Aurobindo Pharma's plans to sell US-based Natrol to Kishore Biyani looking for mutual settlement, here are top headlines this morning